YMAB News

Latest breaking news and updates for YMAB stock.

Track all markets on TradingView

Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals. C...

Will the outcome of the investigation affect the broader sector sentiment toward similar biotech tender offers? How might this news influence short‑interest and potential short‑covering rallies? What are the potential downstream effects on Y‑mAbs’ pipeline milestones and cash‑flow forecasts?
Lawsuits
19 days ago
Read more businesswire

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development an...

How might the sentiment score of 30 (presumably neutral) influence investor sentiment and trading volume for YMAB? Are there any upcoming catalysts (e.g., FDA meetings, conference presentations) that could drive the stock price in the near term? What is the market's perception of the recent corporate developments (e.g., leadership changes, regulatory filings), and could they create short‑term volatility?
Earnings
19 days ago
Read more globenewswire

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

NEW YORK, Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is...

What is the likely short‑term price reaction versus the long‑term impact on Y‑mAbs' valuation? Will the investigation affect the company's ability to raise capital, secure financing, or pursue strategic acquisitions? Is there any historical precedent for similar class‑action suits in the sector and their impact on stock performance?
Lawsuits
19 days ago
Read more prnewswire

Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Y-...

Are there any alternative suitors or competing offers that could emerge as a result of the investigation? Will the sale affect any outstanding debt or convertible securities held by Y‑MABS? What are the implications for Y‑MABS' existing pipeline and future cash flow if the company is acquired by SERB Pharmaceuticals?
Mergers
20 days ago
Read more businesswire

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development an...

How might the earnings outcome affect short‑term trading strategies (e.g., options, volatility trades)? Will the earnings release include any updates on FDA filings or regulatory milestones? What are the margins and cost trends reported for the quarter?
Earnings
20 days ago
Read more globenewswire

YMAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Y-mAbs Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) to SERB Pharmaceuticals for $8.60 per share i...

What potential alternative offers or strategic alternatives could emerge for Y‑mAbs if the sale falls through? What precedent does Halper Sadeh LLC have in similar shareholder rights cases, and what outcomes have they achieved? How might this investigation affect the broader market perception of Y‑mAbs’ pipeline and future financing opportunities?
Mergers
22 days ago
Read more businesswire